BIBW 2992 plus Cetuximab (Erbitux) - 1248971

3 posts / 0 new
Last post
BIBW 2992 plus Cetuximab (Erbitux) - 1248971

Hello everyone,

I would like to know more about this trial that seemed to be very popular last year for people who developed resistance to Tarceva, BIBW 2992 plus Cetuximab (Erbitux).

Is it likely to be FDA approved soon? Are the trials still ongoing?


Reply To: BIBW 2992 plus Cetuximab (Erbitux

Hi Apra, I hope all is well. I think your best bet is to go to the first link I have pasted below and discuss your questions with this group of members. There are several who are or have been on the trial or like you who are looking at the drug combo for future reference. It is very possibly the most extensive collection of comments on the subject to exist (other then the trial itself). The other link is the previous discussion threads in the prior Grace forums.


most recent,

the middle one,

on the first page of the middle one are 2 links to even more previous threads.

Dr West
Reply To: BIBW 2992 plus Cetuximab (Erbitux)

The short answer is that there hasn't been further results reported with this combination, and the primary focus of the company that makes afatinib (Boehringer-Ingelheim) has been on getting it FDA approved as a first line therapy for EGFR mutation-positive patients. I would say that the afatinib/cetuximab story has been a lower priority, but it will perhaps emerge as something they turn to with more effort and funding once they get the approval for afatinib as a single agent in EGFR mutation-positive patients.

-Dr. West

Dr. Howard (Jack) West
Associate Clinical Professor
Medical Oncology
City of Hope Cancer Center
Duarte, CA

Founder & President
Global Resource for Advancing
Cancer Education